Transplant-related survival outcomes. (A) OS according to the treatment arm of patients who received an allogeneic stem cell transplantation in CR1, landmarked from the date of transplantation. The OS at 4 years from CR1 ASCT was 54% after GO2 induction vs 39% after GO1 (P = .021). (B) OS according to the treatment arm of patients without adverse cytogenetics or mutated TP53 censored at ASCT.